In addition, further analysis showed that nobiletin inhibited the development of NSCLC through targets such as TP53, CXCL8, ESR1, PPAR-α, and MMP9 and related signaling pathways. The gene discussed is ESR1; the disease is non-small cell lung carcinoma.